Vaxcyte, Inc.

Stage 2 · Advancing · week 12

As of Oct 22, 2026, Vaxcyte is in Stage 2, the uptrend phase, now in week 12 (since Jul 31, 2026). It closed at $62.85, 14.9% below its 52-week high and above its 200-day average, which is rising.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. More about the company

$62.85

-0.60% today

$9.9B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is PCVX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 18w

S2 24w

S4 22w

S2 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 5w → S2 6w → S3 5w → S2 18w → S3 7w → S2 24w → S3 10w → S4 22w → S1 6w → S4 7w → S1 7w → S2 24w → S3 11w → S2 12w current

Total tracked: 166 weeks across 14 stage runs.

PCVX among Biotechnology96th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…96	PCVXVaxcyte, Inc.	Stage 2 · wk 12	85	+11.2%

vs 52W High

-14.9%

$40.32 lo$73.82 hi

14.9% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 12

1w13w26w

Week 12, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

11.1%

200 DMA: $56.59 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

1.25x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↑

Short-term trend rising strongly

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+11.2%

+15.0%

+3.4%

YTD

+35.3%

+48.4%

Scan Membership

Breakout Watch

Latest: 2024-06-10

8 appearances in last 60 days. First seen: 2021-09-15.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 12 · Vol 1.25x

2026-10-21S2

Wk 12 · Vol 1.37x

2026-10-20S2

Wk 12 · Vol 0.91x

2026-10-19S2

Wk 12 · Vol 1.20x

2026-10-16S2

Wk 11 · Vol 1.55x

2026-10-15S2

Wk 11 · Vol 1.19x

2026-10-14S2

Wk 11 · Vol 0.74x

2026-10-13S2

Wk 11 · Vol 1.32x

2026-10-12S2

Wk 11 · Vol 1.23x

2026-10-09S2

Wk 10 · Vol 2.30x

2026-10-08S2

Wk 10 · Vol 2.08x

2026-10-07S2

Wk 10 · Vol 7.02x

Moving averages & range

50 DMA

$61.49

200 DMA

$56.59

52W High

$73.82

52W Low

$40.32

5D Low

$62.85

Resistance levels (recent highs)

20d High

$73.82

60d High

$73.82

120d High

$73.82

250d High

$73.82

Next resistance

+17.5%

to 20d High

ROE

-36.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.3

Vaxcyte: quick answers

What stage is Vaxcyte in?

As of Oct 22, 2026, Vaxcyte (PCVX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 31, 2026 and is in week 12. What the four stages mean

Is Vaxcyte in an uptrend?

Yes. Vaxcyte is in a Stage 2 uptrend. It trades 11.1% above its 200-day average, which is rising.

How far is Vaxcyte from its 52-week high?

Vaxcyte closed at $62.85 on Oct 22, 2026, 14.9% below its 52-week high of $73.82. Its 52-week low is $40.32.

How has Vaxcyte performed over the past year?

As of Oct 22, 2026, Vaxcyte is up 48.4% over the past year and up 35.3% so far in 2026.

Which sector and industry is Vaxcyte in?

Vaxcyte is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.